2023 World Conference on Lung Cancer (Posters)-EP11.02. Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC : A Multi-Center Prospective Study (Endouble)<b></b>

EP11.02. Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC : A Multi-Center Prospective Study (Endouble) - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to investigate the efficacy and safety of combining Envafolimab, a subcutaneous anti-PD-L1 antibody, with Endostar in advanced non-small cell lung cancer (NSCLC) patients with PD-L1 expression of 1%. The study was a prospective, open-label, multi-center, single-arm phase 2 study. <br /><br />The study included 13 patients with a median age of 67.8 years, and 69% of the patients were male. Most patients were diagnosed at stage IV, with 77% having adenocarcinoma and 23% having squamous cell carcinoma. The primary endpoint of the study was the objective response rate (ORR) and safety. <br /><br />In terms of efficacy, the study showed promising results. The ORR was 62% and the disease control rate (DCR) was 77%, with 8 patients achieving a partial response and 2 patients showing stable disease. The median progression-free survival (mPFS) and median overall survival (mOS) were not reached. <br /><br />In terms of safety, the most common adverse events were elevated ALT (23%), anemia (15%), and hyponatremia (15%), which were all grade 1-2. There were no cases of immune-related pneumonitis or myocarditis. <br /><br />Overall, this study suggests that combining Envafolimab with Endostar has promising efficacy and good tolerability in advanced NSCLC patients with PD-L1 expression of 1%. This combination therapy may provide a new treatment option for these patients. Further prospective studies are expected to confirm these findings.

Asset Subtitle

Xiaodong Jiang

Meta Tag

Speaker Xiaodong Jiang

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

study

efficacy

safety

Envafolimab

subcutaneous anti-PD-L1 antibody

Endostar

non-small cell lung cancer

NSCLC

PD-L1 expression

phase 2 study